Literature DB >> 14595764

Apoptotic gene expression in Paget's disease: a possible role for Bcl-2.

Craig P Brandwood1, Judith A Hoyland, M Chantal Hillarby, Jacqueline L Berry, Michael Davies, Peter L Selby, Andrew P Mee.   

Abstract

Paget's disease of bone is characterized by an increase in both the size and the number of bone-resorbing osteoclasts. An important regulator of osteoclast activity is the process of apoptosis, and any aberration in this process could lead to increased osteoclasis. Analysis using human apoptosis cDNA expression arrays revealed that the apoptotic suppressor, Bcl-2, showed a marked increase in expression in Pagetic bone. In situ hybridization (ISH) and computer-assisted image analysis confirmed that the levels of Bcl-2 transcripts were significantly (p<0.0001) increased in Pagetic osteoclasts. The Bcl-2:Bax transcript ratios were similarly elevated. These findings were confirmed by immunohistochemistry. The Bcl-2 gene promoter sequence from 20 Pagetic patients and controls was analysed. Single nucleotide mutations were identified in three of the Paget's patients and one of the controls. Luciferase reporter analysis showed that the mutations induced a basal 12-fold increase and hydrogen peroxide-induced 19-fold increase in luciferase expression, compared with the normal construct. It is concluded that in Paget's disease, there is an increase in the expression of genes that are involved in the inhibition of apoptosis, notably Bcl-2. The increase in Bcl-2 may be explained in some patients by mutations in the Bcl-2 gene promoter. These results provide a potential explanation for the dramatic increase in osteoclasis seen in patients with Paget's disease. Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14595764     DOI: 10.1002/path.1463

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  8 in total

1.  Osteoclast inhibitory peptide-1 (OIP-1) inhibits measles virus nucleocapsid protein stimulated osteoclast formation/activity.

Authors:  Srinivasan Shanmugarajan; Rimon F Youssef; Parmita Pati; William L Ries; D Sudhaker Rao; Sakamuri V Reddy
Journal:  J Cell Biochem       Date:  2008-07-01       Impact factor: 4.429

2.  Mutant p62P392L stimulation of osteoclast differentiation in Paget's disease of bone.

Authors:  Kumaran Sundaram; Srinivasan Shanmugarajan; D Sudhaker Rao; Sakamuri V Reddy
Journal:  Endocrinology       Date:  2011-08-30       Impact factor: 4.736

Review 3.  Emerging strategies and therapies for treatment of Paget's disease of bone.

Authors:  Laëtitia Michou; Jacques P Brown
Journal:  Drug Des Devel Ther       Date:  2011-04-26       Impact factor: 4.162

4.  Gene expression profile in osteoclasts from patients with Paget's disease of bone.

Authors:  Laetitia Michou; Estelle Chamoux; Julie Couture; Jean Morissette; Jacques P Brown; Sophie Roux
Journal:  Bone       Date:  2009-11-17       Impact factor: 4.398

5.  The p62 P392L mutation linked to Paget's disease induces activation of human osteoclasts.

Authors:  Estelle Chamoux; Julie Couture; Martine Bisson; Jean Morissette; Jacques P Brown; Sophie Roux
Journal:  Mol Endocrinol       Date:  2009-07-09

6.  miR profile in pagetic osteoclasts: from large-scale sequencing to gene expression study.

Authors:  Hoang Dong Nguyen; Martine Bisson; Michelle Scott; Gilles Boire; Luigi Bouchard; Sophie Roux
Journal:  J Mol Med (Berl)       Date:  2021-10-05       Impact factor: 4.599

7.  The adaptor protein p62/SQSTM1 in osteoclast signaling pathways.

Authors:  Stephen McManus; Sophie Roux
Journal:  J Mol Signal       Date:  2012-01-04

8.  Egg White Ovotransferrin Attenuates RANKL-Induced Osteoclastogenesis and Bone Resorption.

Authors:  Nan Shang; Jianping Wu
Journal:  Nutrients       Date:  2019-09-19       Impact factor: 5.717

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.